Biomea Fusion Inc (BMEA) Stock Price, Quote & News

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle con...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 980 9099

Website: biomeafusion.com

Address:

1599 Industrial Road, San Carlos, United States

GODOFUSD Oct. 3 at 8:22 PM

$BMEA Several clinical, regulatory, and data milestones are expected by the end of the year. 1-Icovamenib (BMF-219) - Type 2 Diabetes (T2D) Discussion with the FDA on late-stage development 2-Icovamenib (BMF-219) - Type 2 Diabetes (T2D) 52-week data readout for COVALENT-111 3-Icovamenib (BMF-219) - Type 1 Diabetes (T1D) Open-label data for COVALENT-112 4-Icovamenib (BMF-219) - Diabetes not controlled by GLP-1 Initiation of Phase II study 5-BMF-650 - Obesity IND submission and initiation of Phase I 6-FUSION™ Platform Fourth candidate IND 7-BMF-500 - Acute Leukemia (Oncology) Strategic Partnerships It's just getting started 4.5-7.5 BEOY

0 · Reply

ils85 Oct. 3 at 7:49 PM

$BMEA

0 · Reply

jjrrjjrr Oct. 3 at 7:37 PM

$XTIA $BMEA NFA

0 · Reply

GODOFUSD Oct. 3 at 5:40 PM

$BMEA interesting. they lowered price targets, load up tons of shares and calls, closed their shorts, and now analyst push back the price higher with a buy. We are so close

0 · Reply

ils85 Oct. 3 at 4:21 PM

$BMEA ignore the noise of the clueless here, funding has been soaked and institutions are about to initiate leg after leg going into 2026, news is imminent

0 · Reply

ClenchFists Oct. 3 at 3:58 PM

$BMEA Here we gooo!!

0 · Reply

Patoun Oct. 3 at 3:34 PM

$BMEA ah ah ah I was right to be cautious... From 2.23 to 2.16 in less than hour. No volumes = no trust

0 · Reply

GODOFUSD Oct. 3 at 3:24 PM

$BMEA

0 · Reply

Patoun Oct. 3 at 2:26 PM

$BMEA As a reminder about boral capital: last december "D. Boral maintains Buy rating, $128 target on Biomea Fusion after presentations".... So now they post a new price target of $16... Sorry I do not care their objectives...

1 · Reply

Patoun Oct. 3 at 2:21 PM

$BMEA i do not trust them nor I trust anyone regarding reccomandations. I would even be worry when they recommend a stock

0 · Reply

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2025, 7:00 AM EDT - 18 days ago

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Jul 24, 2025, 7:00 AM EDT - 2 months ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jun 23, 2025, 7:00 AM EDT - 3 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 6:28 AM EDT - 3 months ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 17, 2025, 11:15 PM EDT - 3 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Jun 17, 2025, 7:28 PM EDT - 3 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

Jun 17, 2025, 4:33 PM EDT - 3 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

$Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025$

Jun 13, 2025, 6:45 AM EDT - 4 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

$Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia$

May 14, 2025, 4:05 PM EDT - 5 months ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 5, 2025, 4:05 PM EDT - 5 months ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 4:01 PM EDT - 6 months ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:10 PM EDT - 6 months ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 25, 2025, 7:00 PM EDT - 6 months ago

Biomea Fusion Announces Leadership Transition

Mar 24, 2025, 8:30 AM EDT - 6 months ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 3, 2025, 8:00 AM EST - 7 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2025, 8:00 AM EST - 7 months ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Dec 17, 2024, 10:41 AM EST - 10 months ago

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Dec 17, 2024, 8:10 AM EST - 10 months ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 16, 2024, 6:15 PM EST - 10 months ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 12, 2024, 5:02 PM EST - 10 months ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

$Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia$

Dec 9, 2024, 4:01 PM EST - 10 months ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

$Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia$

Dec 6, 2024, 8:00 AM EST - 10 months ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Nov 3, 2024, 11:00 AM EST - 11 months ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 29, 2024, 4:46 PM EDT - 1 year ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 11:00 AM EDT - 1 year ago

An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For Fraud

Oct 26, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Oct 22, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

Oct 21, 2024, 9:00 AM EDT - 1 year ago

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Oct 20, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

$The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions$

Oct 19, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 18, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

$The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions$

Oct 17, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related Infractions

Oct 15, 2024, 4:05 PM EDT - 1 year ago

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

Oct 8, 2024, 11:00 AM EDT - 1 year ago

Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Should Contact The Schall Law Firm

GODOFUSD Oct. 3 at 8:22 PM

0 · Reply

ils85 Oct. 3 at 7:49 PM

$BMEA

0 · Reply

jjrrjjrr Oct. 3 at 7:37 PM

$XTIA $BMEA NFA

0 · Reply

GODOFUSD Oct. 3 at 5:40 PM

$BMEA interesting. they lowered price targets, load up tons of shares and calls, closed their shorts, and now analyst push back the price higher with a buy. We are so close

0 · Reply

ils85 Oct. 3 at 4:21 PM

$BMEA ignore the noise of the clueless here, funding has been soaked and institutions are about to initiate leg after leg going into 2026, news is imminent

0 · Reply

ClenchFists Oct. 3 at 3:58 PM

$BMEA Here we gooo!!

0 · Reply

Patoun Oct. 3 at 3:34 PM

$BMEA ah ah ah I was right to be cautious... From 2.23 to 2.16 in less than hour. No volumes = no trust

0 · Reply

GODOFUSD Oct. 3 at 3:24 PM

$BMEA

0 · Reply

Patoun Oct. 3 at 2:26 PM

1 · Reply

Patoun Oct. 3 at 2:21 PM

$BMEA i do not trust them nor I trust anyone regarding reccomandations. I would even be worry when they recommend a stock

0 · Reply

Patoun Oct. 3 at 2:19 PM

$BMEA volumes are ridiculously smal. I do not trust this increase. I stay here but xill not buy more now.

2 · Reply

ils85 Oct. 3 at 2:15 PM

$BMEA just a matter of time, very soon imho

0 · Reply

JarvisFlow Oct. 3 at 12:32 PM

D. Boral Capital has updated their rating for Biomea Fusion ( $BMEA ) to Buy with a price target of 16.

2 · Reply

Patoun Oct. 3 at 11:44 AM

$BMEA yeah the inducement probably mean they found a new ceo or cfo, or maybe both. And the amount of 100k stocks is not dillutive. It means that the potential of growth is huge for the stock price, enough to convince world class level ceo or cfo to join in.... A $40 Bmea stock would tranform those 100k stocks into a $4M package... Do never forget that market is huge here. If bmea's drugs are proven to be effective and safe, which for now no one can say otherwide, then a final $150 or 200 stock price is kot a dream at all. See NOVO or LLY's market cap... Is crazy

1 · Reply

hashbridges Oct. 2 at 2:12 PM

$BMEA looking at the inducement means they hired a key VP or C level employee that hasn’t been announced yet. That was basically a $100K signing bonus for someone joining with potential to 10X.

0 · Reply

10xMoonstocks Oct. 1 at 8:05 PM

$BMEA we continue to break through it, but are not seeing the volume to keep it there. Expect it to bounce around a little bit until there is a bigger piece of news

1 · Reply

hashbridges Oct. 1 at 7:43 PM

$BMEA need more cowbell

0 · Reply

GODOFUSD Oct. 1 at 5:24 PM

$BMEA wave 3 target make sens (4.33-5.4). my prediction is +10$ by 1 year from now.

0 · Reply

hashbridges Oct. 1 at 3:55 PM

$BMEA rising under 2X volume. I wonder about when this thing finally breaks free and goes to $3,$4,$4,$6+ will everyone be surprised even though all the signs were there?

0 · Reply

raulsan79trader Oct. 1 at 3:03 PM

$BMEA So here we are, let's see what happens with volume now 👀

0 · Reply

raulsan79trader Oct. 1 at 2:30 PM

$BMEA BIOMEA FUSION, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4) 👀

1 · Reply

highnihilism Oct. 1 at 10:47 AM

0 · Reply

Market Cap	126.75M
Revenue (ttm)	0.00
Net Income (ttm)	-138.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	404,100
Avg Vol	679,606
Day's Range	N/A - N/A
Shares Out	59.51M
Stochastic %K	70%
Beta	-0.12
Analysts	Strong Sell
Price Target	$8.29